Epclusa Tablet, Film Coated
Product Images NDC 61958-2201

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Epclusa (NDC 61958-2201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Epclusa 01)

Chemical structure of Velpatasvir and Sofosbuvir, the active ingredients in Epclusa. The image depicts the molecular arrangement with specific atoms and bonds represented in a standard chemical diagram format.*

FDA Label Image

Chemical Structure (Epclusa 02)

Chemical structure of the active ingredient Velpatasvir in Epclusa, showing its molecular framework with multiple rings and functional groups, consistent with the labeled pharmaceutical compound.*

FDA Label Image

Principal Display Panel (28 Tablet Bottle Label)

An instructional illustration showing a hand holding a rectangular packet with a tear line marked by scissors. The top left corner of the packet features an airplane icon, indicating travel or portability. The image likely demonstrates how to open the packet.*

FDA Label Image

Epclusa 04

Illustration showing a hand holding a packaging pouch with an indicated area to tear open, marked by a dotted line and scissors icon. Arrows at the bottom suggest a motion to pull or separate the pouch sides for opening.*

FDA Label Image

Epclusa 05

A black-and-white instructional illustration showing a person holding a small rectangular blister pack with one tablet partially pushed out using tweezers. The image focuses on the method of removing a tablet from its packaging.*

FDA Label Image

Epclusa 06

Epclusa film-coated tablets packaging label from Gilead Sciences, Inc. The label prominently features the proprietary name 'Epclusa' along with the active ingredients Velpatasvir and Sofosbuvir. It indicates the oral route of administration and displays a combination of strengths including 400 mg and 100 mg tablets. The design uses black text on a white background with clear identification of the dosage form.*

FDA Label Image

Epclusa 07

An instructional illustration showing a hand peeling back a protective seal or label from a container or packaging. The image highlights the proper way to remove the seal by lifting from the corner, indicated by an arrow.*

FDA Label Image

Epclusa 08

An instructional illustration showing a hand tearing open a foil pouch or packet, likely demonstrating how to open a sealed medication package such as a single-dose film-coated tablet pouch.*

FDA Label Image

Epclusa 09

An instructional illustration showing a hand pouring powder from a packet into a bowl containing liquid, with a spoon resting inside the bowl. This image likely demonstrates preparation or administration guidance related to a medication.*

FDA Label Image

Epclusa 10

FDA Label Image

Epclusa 11

An instructional illustration showing a person placing film-coated tablets from a blister strip into their mouth. The image emphasizes oral administration of the medication.*

FDA Label Image

Epclusa 12

Label for Epclusa tablets containing 400 mg sofosbuvir and 100 mg velpatasvir. The label indicates a 28-tablet package and includes directions to take one tablet once daily. Manufactured for Gilead Sciences, Inc., it specifies storage below 30°C and dispensing in the original container. Includes a pharmacist alert regarding medicines that should not be taken with Epclusa.*

FDA Label Image

Epclusa 13

Epclusa tablets packaging label showing 200 mg/50 mg strength of sofosbuvir and velpatasvir tablets. The label indicates the package contains 28 tablets, manufactured for Gilead Sciences, Inc. Instructions include storage below 30°C and dispensing in original container. A pharmacist alert box warns against covering it with a pharmacy label and advises checking for medicines that should not be taken with Epclusa.*

FDA Label Image

Epclusa 14

Epclusa 200 mg/50 mg per packet oral pellets packaging label from Gilead Sciences, Inc. The label specifies the contents as sofosbuvir and velpatasvir combination, indicating that pellets should be swallowed whole and includes a pharmacist note not to cover the ALERT box on the label.*

FDA Label Image

Epclusa 15

Epclusa oral pellets packaging label showing the active ingredients sofosbuvir and velpatasvir. The strength is 150 mg/37.5 mg per packet. The label indicates 28 packets per package and is for prescription use only. Visible manufacturer branding is Gilead Sciences, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.